Enhanced suppressive function of regulatory T cells from patients with immune-mediated diseases following successful ex vivo expansion

Clinical Immunology

Volumn 136, Issue 3, 2010, Pages 329-337

  Cao, Tinghua ^a,d   Wenzel, Sally E ^b   Faubion, William A ^c   Harriman, Gregory ^a,e   Li, Li ^a  

^a Therakos Inc   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^c MAYO CLINIC   (United States)

^d CENTOCOR INC   (United States)

^e Main Line Ventures   (United States)

Author keywords

CD; Expansion; Human; Immune mediated disease; MS; RA; Severe asthma; SLE; Suppression; Treg cells

Indexed keywords

TRANSCRIPTION FACTOR FOXP3;

ADULT; ARTICLE; ASTHMA; BLOOD SAMPLING; CD4+ CD25+ T LYMPHOCYTE; CONTROLLED STUDY; CROHN DISEASE; DONOR; EFFECTOR CELL; EX VIVO STUDY; HUMAN; HUMAN CELL; IMMUNITY; LYMPHOCYTE PROLIFERATION; MULTIPLE SCLEROSIS; PHENOTYPE; PRIORITY JOURNAL; PURIFICATION; REGULATORY T LYMPHOCYTE; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; ULCERATIVE COLITIS;

EID: 77955279253     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2010.04.014     Document Type: Article

References (50)

1. Sakaguchi S., Yamaguchi T., Nomura T., Ono M. Regulatory T cells and immune tolerance. Cell 2008, 133:775-787.
2. + natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol. Rev. 2006, 212:8-27.
3. Roncarolo M.G., Battaglia M. Regulatory T-cell immunotherapy for tolerance to self antigens and alloantigens in humans. Nat. Rev. Immunol. 2007, 7:585-598.
4. Brusko T.M., Putnam A.L., Bluestone J.A. Human regulatory T cells: role in autoimmune disease and therapeutic opportunities. Immunol. Rev. 2008, 223:371-390.
5. + T-regulatory cells: toward therapy for human diseases. Immunol. Rev. 2008, 223:391-421.
6. Tang Q., Bluestone J.A. Regulatory T-cell physiology and application to treat autoimmunity. Immunol. Rev. 2006, 212:217-237.
7. Brunkow M.E., Jeffery E.W., Hjerrild K.A., Paeper B., Clark L.B., Yasayko S.A., Wilkinson J.E., Galas D., Ziegler S.F., Ramsdell F. Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat. Genet. 2001, 27:68-73.
8. Wildin R.S., Ramsdell F., Peake J., Faravelli F., Casanova J.L., Buist N., Levy-Lahad E., Mazzella M., Goulet O., Perroni L., Bricarelli F.D., Byrne G., McEuen M., Proll S., Appleby M., Brunkow M.E. X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy. Nat. Genet. 2001, 27:18-20.
9. Bennett C.L., Christie J., Ramsdell F., Brunkow M.E., Ferguson P.J., Whitesell L., Kelly T.E., Saulsbury F.T., Chance P.F., Ochs H.D. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat. Genet. 2001, 27:20-21.
10. (+) immune regulatory cells inhibits graft-versus-host disease lethality. Blood 2002, 99:3493-3499.
11. (+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J. Exp. Med. 2002, 96:389-399.
12. + regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat. Med. 2003, 9:1144-1150.
13. + regulatory T cells suppress antigen-specific autoreactive immune responses and central nervous system inflammation during active experimental autoimmune encephalomyelitis. J. Immunol. 2002, 169:4712-4716.
14. (+) T cells expressing endogenous T cell receptor chains protect myelin basic protein-specific transgenic mice from spontaneous autoimmune encephalomyelitis. J. Exp. Med. 1998, 188:1883-1894.
15. + cell depletion hastens the onset of severe disease in collagen-induced arthritis. Arthritis Rheum. 2003, 48:1452-1460.
16. + regulatory T cells. Arthritis Rheum. 2005, 52:2212-2221.
17. + regulatory T cells. J. Immunol. 2003, 170:3939-3943.
18. Tang Q., Henriksen K.J., Bi M., Finger E.B., Szot G., Ye J., Masteller E.L., McDevitt H., Bonyhadi M., Bluestone J.A. In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes. J. Exp. Med. 2004, 199:1455-1465.
19. Scalapino K.J., Tang Q., Bluestone J.A., Bonyhadi M.L., Daikh D.I. Suppression of disease in New Zealand Black/New Zealand White lupus-prone mice by adoptive transfer of ex vivo expanded regulatory T cells. J. Immunol. 2006, 177:1451-1459.
20. + regulatory T cells in patients with multiple sclerosis. J. Exp. Med. 2004, 199:971-979.
21. +CD25high T regulatory cell function in patients with active systemic lupus erythematosus. J. Immunol. 2007, 178:2579-2588.
22. Miyara M., Amoura Z., Parizot C., Badoual C., Dorgham K., Trad S., Nochy D., Debré P., Piette J.C., Gorochov G. Global natural regulatory T cell depletion in active systemic lupus erythematosus. J. Immunol. 2005, 175:8392-8400.
23. Ehrenstein M.R., Evans J.G., Singh A., Moore S., Warnes G., Isenberg D.A., Mauri C. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy. J. Exp. Med. 2004, 200:277-285.
24. (+) T-cells from patients with type 1 diabetes. Diabetes 2005, 54:92-99.
25. + T-cells in type 1 diabetes. Diabetes 2005, 54:1407-1414.
26. + CD25(high) T cells in inflammatory bowel disease. Gastroenterology 2005, 128:1868-1878.
27. Takahashi M., Nakamura K., Honda K., Kitamura Y., Mizutani T., Araki Y., Kabemura T., Chijiiwa Y., Harada N., Nawata H. An inverse correlation of human peripheral blood regulatory T cell frequency with the disease activity of ulcerative colitis. Dig. Dis. Sci. 2006, 51:677-686.
28. Miura Y., Thoburn C.J., Bright E.C., Phelps M.L., Shin T., Matsui E.C., Matsui W.H., Arai S., Fuchs E.J., Vogelsang G.B., Jones R.J., Hess A.D. Association of Foxp3 regulatory gene expression with graft-versus-host disease. Blood 2004, 104:2187-2193.
29. + regulatory T cells are numerically deficient in acute and chronic GvHD. Blood 2006, 107:1717-1723.
30. + CD25 high T-regulatory cells in allergic asthma is subjected to TNF-alpha modulation. Allergy 2008, 63:67-74.
31. + regulatory T-cell suppression of allergen-driven T-cell activation to atopic status and expression of allergic disease. Lancet 2004, 363:608-615.
32. Longhi M.S., Meda F., Wang P., Samyn M., Mieli-Vergani G., Vergani D., Ma Y. Expansion and de novo generation of potentially therapeutic regulatory T cells in patients with autoimmune hepatitis. Hepatology 2008, 47:581-591.
33. Putnam A.L., Brusko T.M., Lee M.R., Liu W., Szot G.L., Ghosh T., Atkinson M.A., Bluestone J.A. Expansion of human regulatory T-cells from patients with type 1 diabetes. Diabetes 2009, 58:652-662.
34. + regulatory T cells prevent lethal xenogenic graft versus host disease (GVHD). Cell. Immunol. 2009, 258:65-71.
35. Golovina T.N., Mikheeva T., Suhoski M.M., Aqui N.A., Tai V.C., Shan X., Liu R., Balcarcel R.R., Fisher N., Levine B.L., Carroll R.G., Warner N., Blazar B.R., June C.H., Riley J.L. CD28 costimulation is essential for human T regulatory expansion and function. J. Immunol. 2008, 181:2855-2868.
36. Winship D.H., Summers R.W., Singleton J.W., Best W.R., Becktel J.M., Lenk L.F., Kern F. National Cooperative Crohn's Disease Study: study design and conduct of the study. Gastroenterology 1979, 77:829-842.
37. McDonald W.I., Compston A., Edan G., Goodkin D., Hartung H.P., Lublin F.D., McFarland H.F., Paty D.W., Polman C.H., Reingold S.C., Sandberg-Wollheim M., Sibley W., Thompson A., van den Noort S., Weinshenker B.Y., Wolinsky J.S. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann. Neurol. 2001, 50:121-127.
38. This Official American Thoracic Society Workshop Report Proceedings of the ATS Workshop on Refractory Asthma current understanding, recommendations, and unanswered questions. Am. J. Respir. Crit. Care Med. 2000, 162:2341-2351.
39. Hochberg M.C. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997, 40:1725.
40. Hochberg M.C., Chang R.W., Dwosh I., Lindsey S., Pincus T., Wolfe F. The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis. Arthritis Rheum. 1992, 35:498-502.
41. + cells. Semin. Immunol. 2006, 18:78-88.
42. + T reg cells. J. Exp. Med. 2006, 203:1701-1711.
43. Seddiki N., Santner-Nanan B., Martinson J., Zaunders J., Sasson S., Landay A., Solomon M., Selby W., Alexander S.I., Nanan R., Kelleher A., Fazekas de St Groth B. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J. Exp. Med. 2006, 203:1693-1700.
44. + regulatory T cells cultured with rapamycin. J. Immunol. 2007, 178:320-329.
45. + regulatory T cells of both healthy subjects and type 1 diabetic patients. J. Immunol. 2006, 177:8338-8347.
46. + T cells. J. Immunol. 2006, 177:944-949.
47. Vignali D.A., Collison L.W., Workman C.J. How regulatory T cells work. Nat. Rev. Immunol. 2008, 8:523-532.
48. Riley J.L., June C.H., Blazar B.R. Human T regulatory cell therapy: take a billion or so and call me in the morning. Immunity 2009, 30:656-665.
49. Esensten J.H., Wofsy D., Bluestone J.A. Regulatory T cells as therapeutic targets in rheumatoid arthritis. Nat. Rev. Rheumatol. 2009, 5:560-565.
50. Zhou X., Bailey-Bucktrout S.L., Jeker L.T., Penaranda C., Martínez-Llordella M., Ashby M., Nakayama M., Rosenthal W., Bluestone J.A. Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo. Nat. Immunol. 2009, 10:1000-1007.